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doi:10.1016/j.jtcvs.2005.12.059bjective: Bronchiolitis obliterans syndrome has become the most limiting factor
or long-term outcome after lung transplantation. Redo lung transplantation was
erformed for end-stage bronchiolitis obliterans syndrome. Long-term outcome was
ompared with that after primary lung transplantation as well as with other indica-
ions for retransplantation.
ethods: Of 614 lung transplantation procedures performed at our institution, 54
8.5%) were redo transplants. These were stratified into different groups according to the
ndication for redo transplantation, including chronic graft failure/bronchiolitis obliter-
ns syndrome, acute graft failure, and posttransplantation airway complications. Long-
erm survival was compared with that of the primary lung transplantation cohort, thereby
especting the need for pretransplant mechanical ventilatory support in a subanalysis. In
ddition, recurrence of bronchiolitis obliterans syndrome after redo lung transplantation
as compared with the occurrence of bronchiolitis obliterans after primary transplan-
ation.
esults: A 1-year survival of 50% was achieved after redo lung transplantation for
cute graft failure and airway complications as well as after primary lung trans-
lantation in patients with pretransplant ventilatory support. Retransplantation for
ronchiolitis obliterans syndrome revealed superior 1- (78%) and 5-year (62%)
urvivals, which were not different from those of first-time lung transplant recipi-
nts. In addition, we found a similar incidence of bronchiolitis syndrome after
etransplantation for BOS compared with its occurrence after primary lung trans-
lantation.
onclusion: Redo lung transplantation for end-stage bronchiolitis obliterans syn-
rome leads to acceptable long-term outcome in selected patients. Future analyses
f redo lung transplantation data should generally stratify bronchiolitis obliterans
yndrome from other indications with higher mortality.
ung transplantation (LTx) has become an established therapeutic modality
for a variety of end-stage pulmonary diseases. However, since most technical
obstacles during transplantation and common complications in the early
hase after transplantation have been properly addressed, the remaining major
hallenge is the prevention and treatment of bronchiolitis obliterans syndrome
BOS). In the literature the overall incidence of BOS within the first 5 years after
rimary LTx is approximately 50%.1 In addition, data suggest a lower chance 
0-year survival after LTx in patients with BOS. Currently, BOS is the cause of
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TXeath in 17% of patients after LTx.2 This is, beside infec-
ion, the second leading cause of death and the number is
rowing with the increasing number of LTx procedures
orldwide. BOS is a multifactorial disease and, apparently,
he prevention of BOS by any single means is imposs3
lthough promising approaches to the prevention of BOS
ave been reported,4 strategies that have used new imm-
osuppressants have not provided satisfactory results.
Various treatment protocols for BOS were also suggest5
owever, the delay of further deterioration of lung function in
OS patients was called successful and many studies did not
ddress the possible role of acute rejection or infection epi-
odes after LTx in the context of BOS development.6,7 There-
ore, some improvements seen in the course of BOS may be
ue to successful treatment of acute rejection or infection.
End-stage BOS eventually leads to lung failure. There-
ore, it is our policy to offer pulmonary retransplantation
re-LTx) to patients with BOS in whom other strategies in
he treatment of BOS have failed and in whom no organs
ther than the lungs are impaired. This strategy has been
riticized as a waste of scarce donor organs in the past, since
e-LTx was identified as a potential risk factor for survival
fter LTx. Beside BOS, re-LTx has also been performed for
cute graft failure and bronchial healing complications in
he early postoperative period after LTx. In outcome anal-
ses, re-LTx was not stratified regarding these three indi-
ations. We analyzed the outcome in these three subgroups
f re-LTx indications and compared the findings with those
f primary LTx candidates at the Hannover Thoracic Trans-
lant Program. In a subanalysis, the outcome after primary
Abbreviations and Acronyms
BOS  bronchiolitis obliterans syndrome
LTx  lung transplantation
re-LTx pulmonary retransplantation08 The Journal of Thoracic and Cardiovascular Surgery ● AuguTx as well as after LTx in patients with pre-LTx mechan-
cal ventilatory support was compared.
atients and Methods
t our center 614 lungs transplant procedures were performed
ntil January 1, 2004. Of those, 54 (8.5%) were re-LTx proce-
ures. Major indications for primary LTx were pulmonary fibrosis,
mphysema, and cystic fibrosis; 45% were female and 55% were
ale recipients. For acute graft failure after primary LTx, 10
e-LTx procedures were performed, out of which 5 (50%) were
nitially transplanted for pulmonary fibrosis. Figure 1 depicts
ndications for primary LTx compared with those for re-LTx for
cute graft failure. In this group only one recipient was female. In
patients re-LTx was performed for airway complications, either
evere dehiscence of the bronchial anastomosis (n 5) or scarring
f the airways with significant obstruction (n  2), when inter-
entional procedures to re-establish the bronchial lumen have
ailed. In the majority of these patients, the initial reason for
ransplantation was advanced lung emphysema. In this subgroup,
8% of the recipients were male and 42% were female patients.
or chronic graft failure (BOS), 37 re-LTx procedures were per-
ormed, as shown in Figure 2. The leading indication in this 
as cystic fibrosis (46%) followed by idiopathic pulmonary hy-
ertension (19%). In this group, 65% of patients were female. In
he group of primary transplant recipients, mean age was 42 years
16-66 years). For acute graft failure, re-LTx was performed in
atients with a mean age of 38 years (range 23-54 years, Fig
ecipients in the chronic graft failure group were younger (mean
6 years; range 16-54 years) and patients of the airway complica-
ion group were oldest (mean 47 years; range 26-59 years).
tatistical Analysis
ata were prospectively recorded and retrospectively analyzed.
ll data are expressed as mean  SE. Continuous data were
nalyzed by repeated-measures analysis of variance. For data
ithout repeated measurement, analysis of variance was applied.
ll data were analyzed with the Statistical Program of Social
ciences (SPSS for MS Windows, version 11.0, SPSS, Inc, Chi-
ago, Ill).
Figure 1. Indications for primary lung trans-
plantation compared with re-LTx for acute
graft failure. Tx, Transplantation; gf, graft fail-
ure; ppht, primary pulmonary hypertension;
pht-sec, secondary pulmonary hypertension.st 2006
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TXesults
erioperative survival (1 month) was 91% in the primary
ransplant cohort. There was no statistical difference
hen comparing this group with that of re-LTx proce-
ures in patients with airway complications or BOS,
hich is illustrated in Figure 4. Only in the acute 
ailure group was a high early mortality of 20% seen.
fter 3 months, survival in all groups was similar except
or the acute graft failure group, in which the survival
as only 71%. In the later follow-up only a 50% 1-year
urvival was achieved in the acute graft failure group.
owever, BOS patients and primary LTx patients had
omparable 5-year survivals of 62% and 63%, respec-
ively. In the airway complication group, a 2-year sur-
ival of only 33% was achieved. For airway complication
s well as for acute graft failure, the impairment of
ong-term survival was of statistical significance com-
ared with BOS and primary LTx patients (P  .001).
igure 3. Age of transplant recipients by indication. tf, Trans-
lant; gf, graft failure. r
The Journal of Thoracicft
Table 1 compares the causes of deaths after re-LT
imilar pattern was found in all groups with the exception of
he airway complication group. The leading cause of death
as infection, followed by chronic graft failure. In the
irway complication group, however, recurrence of dehis-
ence in 3 recipients was the leading cause of death.
Analyzing a cohort of subsequent primary LTx recipients
eceiving transplants between January 1998 and 2001 (Figur
echanical ventilation was required before LTx in 39 pa-
ients, who were also listed for high-urgency LTx. In the
ame time period, 112 LTx procedures were performed in
12 elective cases without prior mechanical ventilation. In
lective transplants, a perioperative survival of 92% was
chieved, leading to a 2-year survival of 78% and a 4-year
urvival of 64%. However, in the patients with prior me-
hanical ventilation, reduced survival was found (P  .01).
n this cohort, perioperative mortality was 21% and 1- and
-year survival was 50% only.
Figure 2. Indications for re-LTx for airway
complications compared with re-LTx for chron-
ic graft failure (BOS). gf, Graft failure; ppht,
primary pulmonary hypertension; pht-sec, sec-
ondary pulmonary hypertension.
igure 4. Survival of all primary transplant recipients and of
e-LTx candidates by indication. TX, Transplant; gf, graft failure.
and Cardiovascular Surgery ● Volume 132, Number 2 409
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TXComparing the incidence of BOS in the group of chronic
raft failure patients with primary LTx recipients, similar
reedom from BOS was found in a follow-up period of 4
ears (Figure 6). Both groups revealed a freedom from 
f 70% after 2 years and of 50% after 4 years.
iscussion
e have compared the outcome after re-LTx with that after
rimary LTx at our program and report the data as a single-
enter experience. All LTx procedures included to this study
ere performed over a period of more than 15 years. Cer-
ainly, early experiences led to different decisions in the
ater patients. Re-LTx for airway complications were rare in
he last 5 years of this study, as were retransplants for acute
raft failure. This is in part due to the growing experience
rom previous patients and due to a “quantum leap” in the
uality of lung preservation.8 In contrast, re-LTx for chron
raft failure is a current topic, especially with regard to the
rowing number of recipients in whom severe BOS devel-
ps, despite all other efforts at prevention and treatment.
owever, some trends were noticed in our study: First,
irway complications seem to be more common in elderly
en with emphysema. Second, re-LTx for acute graft fail-
ABLE 1. Causes of death after re-LTx
First LTx
(n  210)
Acute graft
failure
(n  6)
Chronic
graft failure
(n  16)
Airway
complications
(n  6)
cute rejection 2 0 0 1
nitial graft failure 5 0 1 0
hronic graft
failure
35 1 3 1
nfection 80 4 4 1
alignancy 8 0 2 0
ther 80 1 6 3
auses of death of all primary LTx recipients and of re-LTx candidates by
ndication.10 The Journal of Thoracic and Cardiovascular Surgery ● Augure in our cohort was most common in patients with fibrosis
nd idiopathic pulmonary hypertension, probably indicating
possible role of high pulmonary pressures during the reper-
usion period or involvement of immunologic mechanisms on
he development of acute lung graft failure. Third, indications
or re-LTx in the chronic graft failure cohort were limited to
ounger patients with an otherwise promising prognosis, such
s cystic fibrosis as the indication for primary LTx, with a
ender distribution of two-thirds female and one-third males.
n this group, long-term survival as well as the incidence of
OS revealed a similar course to that of first-time recipients.
Novick and colleagues9 analyzed many aspects of r
Tx a decade ago in a remarkable report on 160 re-LTx
rocedures performed at 35 centers worldwide. One of the
redictors of early survival was the patients’ ambulatory
tatus.9 This observation is strongly supported by our d
n that survival was best in chronic graft failure, which
epresents an elective procedure in ambulatory patients. In
ontrast, all patients having re-LTx procedures for “airway
omplications” or “acute graft failure” were on mechanical
entilation at the time of re-LTx and, thus, not ambulatory
efore the operation. To further support this intriguing find-
ng, we included a previous analysis of first-time transplants
tratified by the presence and absence of mechanical venti-
atory support before primary LTx. Again, patients on me-
hanical ventilation showed a 1-year survival of 50% only,
hich is comparable with the outcome of patients with
entilatory support followed by re-LTx in this study. In the
bove-mentioned investigation by Novick and associate9
nother striking finding was the high incidence of recur-
ence of BOS in patients having chronic graft failure. A
reedom of BOS of only 31% was found after 3 years. This
esult was clearly improved within the past 10 years to
chieve similar outcome to primary transplantation. An-
ther difference is that severe impairment of long-term
urvival was observed in recipients with BOS stage III. This
eems to be attributable to the low number (n  7), because
n our patients the indication for re-LTx was BOS III. In
Figure 5. Cumulative survival of 151 consec-
utive patients undergoing primary LTx with
and without mechanical ventilation before
LTx.st 2006
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TXnother report by the same authors, no difference in survival
as observed according to the predominant indication of
e-LTx (BOS, airway complication, or acute graft failure10
n all groups 1-year survival was below 50%. However,
ven in these early experiences a significant improvement of
urvival was found when re-LTx was performed after 1992.
hus, it seems that improvements of re-LTx allow us to
istinguish between high- and low-risk indications for re-
Tx now. This is leading to two conclusions: First, in
egistry reports the risk of “retransplantation” should be
tratified to “re-LTx for acute graft failure” and “re-LTx for
hronic graft failure.” Second, and more provocative, there
s no medical reason not to do a re-LTx for chronic graft
ailure, if patients otherwise fulfill the criteria for LTx in
eneral. Ethical issues of retransplantation in an era of
evere donor organ shortage cannot be answered by medical
acts. Furthermore, in a quality of life survey conducted at
ur program by Künsebeck and coworkers, more than 80%
f LTx recipients would decide again for transplantation,
egardless the degree of BOS (Figure 7). Only in the 
II group, 4.7% of patients would not decide for LTx again.
In 1998, an update of the international results on pulmonary
etransplantation including 230 patients was published.11 The
mpairment of ventilatory support to postretransplant out-
ome was clearly identified. It was also shown that both
ncreasing experience in the field of re-LTx in a single
enter and re-LTx for BOS performed more than 2 years
fter primary LTx were associated with reasonable outcome
n terms of survival and recurrence of BOS. These findings
re now strongly supported by our data. It was concluded by
he authors, that high-risk patients, such as those with pre-
Tx ventilatory support, “should not be considered for
e-LTx with similar priority as other candidates.” This again
eems to be a difficult ethical issue, which could be an-
wered in a different way by other than medical profession-
ls, because a survival benefit of 50% for up to 3 years could
e demonstrated in these patients. We believe that this prob-
igure 6. Freedom from BOS in long-term survivors after primary
Tx and re-LTx for BOS. Differences are not significant (log rank:
 .09). TX, Transplant.em applies to all patients with ventilatory support before c
The Journal of ThoracicS
Tx, not only to retransplant candidates. Another issue in
e-LTx is whether it should be offered to children with lung
ailure after LTx. Clearly, we do not provide evidence
egarding re-LTx in children under the age of 16 years.
owever, in 1998 it was reported that re-LTx should be
ffered to children with severe graft dysfunction.12 Al-
hough the actuarial survival was shown to be only 58%
fter 2 years, the option of living donor transplantation was
ddressed to overcome the problem of availability of suit-
ble grafts. Recently, this opinion was further supported
n an updated report,13 but we strongly believe that t
pproach should still be questioned until it has proven its
enefit.
In 2003, Brugiere and coworkers14 reported on thei
e-LTx experience of 15 patients with BOS in France. In all
ases, unilateral LTx was the procedure of choice and a
-year survival of only 53% was achieved. This raises the
uestion weather long-term outcome was impaired by the
echnique of single LTx, since most of the recipients in our
eries received a bilateral re-LTx.
In conclusion, re-LTx represents an effective treatment
ption for end-stage chronic graft dysfunction. Acceptable
ong-term results can be achieved when patient selection
riteria include “ambulatory patient” and freedom from
reoperative mechanical ventilatory support. Re-LTx for
cute graft failure and airway complications has become
are because of the very poor outcome. Chance for survival
f such re-LTx candidates is comparable with that of recip-
ents who undergo primary LTx with ventilatory support
efore transplantation. A future debate including ethical
spects seems to be necessary to balance possible individual
urvival benefits of these high-risk patients and the better
ong-term outcome of non–ventilator supported transplant
igure 7. Surveillance of quality of life (QoL) in lung transplant
ecipients at the Hannover Thoracic Transplant Program.15andidates.
and Cardiovascular Surgery ● Volume 132, Number 2 411
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